Proteomics Exploration of Chronic Lymphocytic Leukemia_Crimson Publishers
Proteomics Exploration of Chronic Lymphocytic Leukemia by Tiara Griffen in Journal of Cancer Research
Crimson Publishers_ Novel Approaches in Cancer Study
Chronic Lymphocytic Leukemia (CLL) is an adult heme malignancy characterized by the presence of mature-appearing CD5+ B cells in the blood, bone marrow, and secondary lymphoid organs [1]. In the United States, there will be an estimate of 20,720 new cases and 3,930 deaths according to the American Cancer Society statistics. Symptoms include swollen lymph nodes, frequent infections, and fatigue which negatively impacts the quality of life of people affected [1]. CLL is heterogeneous in its progression and clinical outcomes. Factors that contribute to the heterogeneity include the immunoglobulin heavy chain (IGHV) status and chromosomal aberrations [2,3]. There are two subtypes of CLL: Unmutated(U-CLL) and Mutated CLL(M-CLL). 40% and 60% of patients are diagnosed with unmutated and mutated CLL. U-CLL is characterized by the presence of CLL cells that have less than two percent of their IGHV mutated, whereas M-CLL cells have more than two percent mutated [4]. U-CLL is the more aggressive phenotype [2]. These cells have increased responsiveness to antigens that bind the B cell receptor (BCR) versus M-CLL cells [5]. M-CLL is the more indolent phenotype. Increased BCR signaling results in increased cell survival and proliferation [5].
https://crimsonpublishers.com/nacs/fulltext/NACS.000553.php
For More Articles on Journal of Cancer Research Please click on: https://crimsonpublishers.com/nacs/
For more open access journals in Crimson Publishers
please click on the link https://www.scilit.net/publisher/9410/10350
Comments
Post a Comment